triciribine
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2006 (NCT00363454)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ptx-200
- triciribine phosphate monohydrate
- triciribine phosphate monohydrate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02930109 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | Prescient Therapeutics, Ltd., University of South Florida |
| NCT00363454 | Phase 1 | Apr 1, 2006 | Prescient Therapeutics, Ltd., University of South Florida, VioQuest Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Prescient Therapeutics, Ltd. | For profit | 2 | 2 | 2 | 2006 |
| University of South Florida | Academic/Hospital | 2 | 0 | 2 | 2006 |
| VioQuest Pharmaceuticals | For profit | 1 | 0 | 1 | 2006 |
3 organizations
Page 1 / 1